In summary, our study demonstrates that SIRT2 plays an important tumour‐suppressive role in CRC progression and serves as a promising diagnostic or prognostic biomarker, clinical predictor and therapeutic target for CRC diagnosis and treatment. The gene discussed is SIRT2; the disease is colorectal carcinoma.